Scientific publications

A list of recent posters presented at congresses and articles published in peer reviewed scientific journals.

Project	Indication
ODM-203 (targeted FGFR+VEGFR inhibitor)	Solid tumours
Congress posters ESMO 2018 Cholangiocarcinoma Foundation Annual Conference 2017 ESMO 2016 ASCO 2016 Scientific articles Holmström et al; Mol Can Ther	19-23 October 2018 1-3 February 2017 7-11 October 2016 3-7 June 2016 9 October 2018	Phase 1/2 study of ODM-203, e selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumors Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumors Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumors Dose escalation study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumors ODM-203 a selective inhibitor of FGFR and VEGFR, shows strong anti-tumor activity, and induces anti-tumor immunity. Open access
ODM-207 (BET protein inhibitor)	Cancer
Congress posters AACR Annual Meeting 2019 EORTC 2018 AACR Annual Meeting 2018 2nd European Cancer Epigenetics Conference AACR Annual Meeting 2017	29 March - 4 April 2019 13-16 November 2018 14-18 April 2018 11-13 May 2017 1-5 April 2017	ODM-207 - a novel BET bromodomain inhibitor with antitumor activity in nonclinical models of ER+ breast cancer Antitumor activity of ODM-207, a novel BET bromodomain inhibitor, in nonclinical models of ER+ breast cancer as single agent and a a combination treatment Therapeutic targeting of estrogen receptor positive breast cancer with the BET bromodomain inhibitor ODM-207 Targeting cancer with a novel BET bromodomain inhibitor Targeting cancer with a novel BET bromodomain inhibitor Immune-mediated anti-tumor activity with a clinical stage BET bromodomain inhibitor ODM-207 in pre-clinical models
ODM-208 (CYP11A1 inhibitor)	Prostate cancer (CRPC)
Congress posters ENDO 2019 ESMO 2018 ASCO GU 2018 The 24th Annual PCF Scientific Retreat ESMO 2017	23-26 March 2019 19-23 October 2018 8-10 February 2018 5-7 October 2017 8-12 September 2017	CYP11A1 Inhibition as a Therapeutic Approach for the Treatment of Castration Resistant Prostate Cancer CYP11A1 inhibitor as a therapeutic approach for the treatment of castration resistant prostate cancer CYP11A1 inhibitor as a threapeutic approach for the treatment of castration resistant prostate cancer ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer
ODM-209 (CYP11A1 inhibitor)	Prostate cancer (CRPC), breast cancer